<SEC-DOCUMENT>0001279569-19-002139.txt : 20191018
<SEC-HEADER>0001279569-19-002139.hdr.sgml : 20191018
<ACCEPTANCE-DATETIME>20191018165118
ACCESSION NUMBER:		0001279569-19-002139
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20191018
FILED AS OF DATE:		20191018
DATE AS OF CHANGE:		20191018

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		191158257

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16 </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of October 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410 </B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway, Vancouver,
British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings">x</FONT>
Form 40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>EXHIBITS INCLUDED AS PART OF THIS REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 12%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD STYLE="padding-right: 21.45pt; padding-left: 0.05pt; text-indent: -0.05pt"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">Press release, dated October 18, 2019.</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Exhibit 99.1 of this Report on Form 6-K shall be incorporated by
reference into the registrant&rsquo;s Registration Statements on Form F-3 (File No. 333-222654, File No. 333-225969 and File No.
333-234136) and Form S-8 (File No. 333-225056) under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT>
        <FONT STYLE="font-size: 10pt">P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT> <FONT STYLE="font-size: 10pt">I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 107%">Date: October 18,
    2019</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt; line-height: 107%">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT> <FONT STYLE="font-size: 10pt">W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>





<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED OCTOBER 18, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;<IMG SRC="essalogo.jpg" ALT="" STYLE="width: 177px; height: 76px"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA Announces Changes to its Board of
Directors</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /CNW/
-&nbsp;ESSA Pharma Inc. (&quot;<B>ESSA</B>&quot; or the &quot;<B>Company</B>&quot;) (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical
company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed
to the board of the directors of the Company (the &quot;<B>Board</B>&quot;) pursuant to a nomination right granted to Clarus Lifesciences
III, L.P., now managed by Blackstone Life Sciences. The Company also announces that Otello Stampacchia, who has represented Omega
Funds, has resigned from the Board as he focuses on new investments.&nbsp;&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">David R. Parkinson, President and Chief Executive
Officer, said, &quot;We are extremely appreciative of Otello's support as a member of the Board of Directors.&nbsp; Ari's perspectives
will be valuable as we execute on the path towards a successful IND filing of EPI-7386.&quot;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Dr. Brettman is currently a Principal in the
Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Dr. Brettman
joined Clarus in September 2014. Dr. Brettman is currently a member of the Board of Directors of Praxis Precision Medicines and
Anthos Therapeutics as well as an Observer on the Board of Directors of Talaris Therapeutics.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Dr. Brettman completed a residency in internal
medicine and a fellowship in cardiology at Massachusetts General Hospital (&quot;MGH&quot;) and was also a National Institutes
of Health-sponsored post-doctoral fellow at the MGH Center for Systems Biology. He received his M.D. from Duke University and his
A.B. in History and Science from Harvard College. While a medical student, he was a Sarnoff Cardiovascular Research Foundation
Fellow at Stanford University, where he studied angiogenesis.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About ESSA Pharma Inc.</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA is a pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer in patients whose disease
is progressing despite treatment with current therapies. ESSA's proprietary &quot;aniten&quot; compounds bind to the N-terminal
domain of the androgen receptor (&quot;<B>AR</B>&quot;), inhibiting AR driven transcription and the AR signaling pathway in a unique
manner which bypasses the drug resistance mechanisms associated with current anti-androgens. The Company is currently progressing
IND-enabling studies and expects to file an IND with the FDA for EPI-7386 in the first calendar quarter of 2020. For more information,
please visit www.essapharma.com or follow us on Twitter under @ESSAPharma.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Prostate Cancer</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Prostate cancer is the second-most commonly
diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the
prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal
treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels
of testosterone, disease progression despite castrate levels of testosterone generally represents a transition to the lethal variant
of the disease, metastatic CPRC (&quot;<B>mCRPC</B>&quot;), and most patients ultimately succumb to the illness. The treatment
of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options are needed
to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide,
or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease
progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies,
ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies
are no longer effective.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Forward-Looking Statement Disclaimer</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">This release contains certain information which,
as presented, constitutes &quot;forward-looking information&quot; within the meaning of the Private Securities Litigation Reform
Act of 1995 and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events
and often addresses expected future business and financial performance, containing words such as &quot;anticipate&quot;, &quot;believe&quot;,
&quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;, &quot;potential&quot;, &quot;promising&quot;,
&quot;refocus&quot;, statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;,
or &quot;will&quot; be taken or occur, or other similar expressions and includes, but is not limited to, statements about Mr. Stampacchia's
consultancy role with the Company.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking statements and information
are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict,
and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied
thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and
are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such
statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited
to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and economic conditions.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking information is developed based
on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated
December 13, 2018 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile on the SEDAR website
at www.sedar.com, ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile.
Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made
and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances
should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned against
attributing undue certainty to forward-looking statements.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><I>Neither the TSXV nor its Regulation Service
Provider (as that term is defined in the policies of the TSXV accepts responsibility for the adequacy or accuracy of this release.</I></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><IMG SRC="image_001.gif" ALT="Cision" STYLE="height: 12px; width: 12px">View
original content:http://www.prnewswire.com/news-releases/essa-announces-changes-to-its-board-of-directors-300941375.html</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content: http://www.newswire.ca/en/releases/archive/October2019/18/c2719.html</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001633932</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Company Contact: David Wood, Chief
Financial Officer, ESSA Pharma Inc., Contact: (778) 331-0962; Investor Relations Contact: Alan Lada, Vice President, Solebury Trout,
Contact: (617) 221-8006</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 16:15e 18-OCT-19</P>



<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>essalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 essalogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJM&=)VD=5'$0JJ\2W11161L%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?*NI?\A:]_Z^)/\ T(U]55\JZE_R%KW_
M *^)/_0C7IY9O+Y'DYKM'YE:BBKFEZ9=ZSJ4.GV2*]S,2$5F"@X!)Y/L#7K-
MI*[/&2;=D4Z*[+_A5GBS_GR@_P# E*/^%6>+/^?*#_P)2LOK%'^9&WU6M_*S
MC:*[+_A5GBS_ )\H/_ E*/\ A5GBS_GR@_\  E*/K%'^9!]5K?RLXVBNR_X5
M9XL_Y\H/_ E*/^%6>+/^?*#_ ,"4H^L4?YD'U6M_*SC:](^#'_(R:A_UZ?\
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MY'SA17H^K?![5K8L^EWD%['V23]V_P#@?S%<5J/A[6=()%_IEU !_&T9*_\
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MB;GDOQEUO+V.AQ-P/])G /U"#_T(_E7E%:?B+5WU[Q#?:DV<3RDH#V0<*/R
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MJ<ZZGNY;5YJ?(^A)1117 >D%%%% !1110 4444 %%%% !1110 4444 %%%%
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M[6_V3WKYQU72KW1=0DL=0@:&=.H/1AZ@]P?6OJ>LCQ!X:TSQ+9?9M1@#[?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#=A#  , '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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" #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
